BIOA
BioAge Labs, Inc
7.20$
-8.6%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Cash Flow
BioAge Labs, Inc (BIOA) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -19 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 13 | Q2 13 | Q3 13 | Q4 13 | Q1 14 | Q2 14 | Q3 14 | Q4 14 | Q1 15 | Q2 15 | Q3 15 | Q4 15 | Q1 16 | Q2 16 | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -14 | -2.2 | -5.3 | -5.9 | -4.9 | -3.1 | -2.3 | -12 | -5.9 | -9.6 | -6.9 | -9.7 | -20 | -5.4 | -7.4 | -4.5 | -11 | -8.2 | -5.8 | -5.3 | -10 | -11 | -7.8 | -8.5 | -16 | -16 | -15 | -5.1 | -17 | -20 | -16 | -28 | -24 | -19 | -88 | |
| 0.6 | 0.7 | 0.2 | 0.2 | 0.3 | 0.3 | 0.3 | 0.5 | 0.6 | 1.0 | 0.7 | 1.9 | 2.2 | 2.4 | 2.4 | 2.2 | 1.8 | 1.9 | 2.0 | 3.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.1 | 0.1 | 0.1 | 0.3 | |
| 2.4 | 2.1 | 1.0 | 1.3 | 1.5 | 3.0 | 1.0 | 1.4 | 1.5 | 1.5 | 0.8 | 0.9 | 0.9 | 0.8 | 0.9 | 0.9 | 2.3 | 1.0 | 0.8 | 1.1 | 0.7 | 0.8 | 0.8 | 0.8 | 0.9 | 1.6 | 1.8 | 2.7 | 2.9 | 3.2 | 2.8 | 2.7 | 4.3 | 4.3 | 14 | |
| 15 | 88 | -11 | -16 | -16 | -28 | 19 | -19 | -29 | 15 | -18 | -21 | 20 | -8.8 | 1.3 | -8.0 | 17 | 1.9 | -3.7 | 2.4 | -0.3 | 1.2 | 1.3 | 4.5 | -4.7 | -3.9 | 6.2 | 14 | -7.5 | -1.8 | 1.2 | -3.7 | -6.0 | 2.8 | -5.7 | |
| 0.0 | 2.1 | 2.5 | 8.2 | 13 | 20 | 33 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.3 | 0.0 | 0.4 | 0.2 | 0.0 | 0.1 | 0.0 | 0.3 | 0.5 | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -0.1 | -0.1 | -0.1 | – | – | 0.0 | -0.3 | 0.0 | -78 | -16 | 13 | -14 | -47 | -165 | -213 | |
| – | – | 0.1 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| -12 | -91 | 7.4 | 12 | -73 | 19 | -24 | 28 | -26 | -23 | 14 | 27 | -14 | 8.5 | -10 | -0.2 | -5.3 | -0.4 | -4.5 | 5.6 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -1.5 | -1.5 | -1.5 | -1.5 | -1.5 | -1.5 | -1.5 | -1.2 | -5.7 | |
| 0.8 | 96 | 0.1 | 3.0 | 8.1 | 2.6 | 56 | 12 | 11 | 55 | 3.6 | -16 | 27 | -2.8 | 18 | 5.0 | 0.0 | 8.7 | 10 | -0.2 | 23 | 12 | 0.0 | -1.0 | 168 | -2.4 | 191 | 25 | -1.5 | -1.5 | -1.5 | 16 | 124 | 16 | 154 | |
| -14 | 91 | -7.4 | -12 | -11 | -19 | 24 | -28 | -25 | 23 | -14 | -27 | 7.1 | -8.5 | 10 | 0.2 | -11 | 0.4 | 4.5 | -5.6 | 13 | 1.4 | -7.9 | -9.6 | 152 | -18 | 175 | 20 | -97 | -37 | -4.8 | -27 | 53 | -168 | -146 | |
| -14 | -4.2 | -7.8 | -14 | -18 | -23 | 30 | -12 | -5.9 | -9.6 | -6.9 | -9.7 | -20 | -5.4 | -7.4 | -4.5 | -11 | -8.2 | -5.8 | -5.3 | -10 | -11 | -7.9 | -8.5 | -16 | -16 | -15 | -5.2 | -18 | -20 | -16 | -28 | -24 | -20 | -88 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.